-
Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.
Rudolph K, Diaz I, Hejazi N, van der Laan M, Luo S, Shulman M, Campbell ANC, Rotrosen J, Nunes E. Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables. Addiction 2021;116(8):1935-2253.
-
Emergency department patients with untreated opioid disorder: A comparison of those seeking versus not seeking referral to substance use treatment.
Coupet E Jr, D’Onofrio G, Chawarski M, Edelman EJ, O’Connor PG, Owens P, Martel S, Fiellin DA, Cowan E, Richardson L, Huntley K, Whiteside LK, Lyons MS, Rothman RE, Pantalon M, Hawk K. Emergency department patients with untreated opioid disorder: A comparison of those seeking versus not seeking referral to substance use treatment. Drug and Alcohol Dependence 2021;219:108428
-
Early implementation of screening for substance use in rural primary care: A rapid analytic qualitative study.
Moore SK, Saunders EC, Hichborn E, McLeman B, Meier A, Young R, Nesin N, Farkas S, Hamilton L, Marsch LA, Gardner T, McNeely J. Early implementation of screening for substance use in rural primary care: A rapid analytic qualitative study. Substance Abuse 2021;42(4):678-691.
-
Integrating telemedicine for medication treatment for opioid use disorder in rural primary care: Beyond the COVID pandemic [commentary].
Hser Y, Mooney LJ. Integrating telemedicine for medication treatment for opioid use disorder in rural primary care: Beyond the COVID pandemic [commentary]. Journal of Rural Health 2021;37(1):246-248.
-
Screening for drug use in primary care: Practical implications of the new USPSTF recommendation [editorial].
Bradley KA, Lapham GT, Lee AK. Screening for drug use in primary care: Practical implications of the new USPSTF recommendation [editorial]. JAMA Internal Medicine 2020;180(8):1050-1051.
-
Are non-abstinent reductions in World Health Organization drinking risk level a valid treatment target for alcohol use disorders in adolescents with ADHD?
Mitchell HM, Park G, Hammond CJ. Are non-abstinent reductions in World Health Organization drinking risk level a valid treatment target for alcohol use disorders in adolescents with ADHD? Addictive Behaviors Reports 2020;12:100312.
-
Impact of 12 step mutual help groups on drug use disorder patients across six clinical trials.
Humphreys K, Barreto NB, Alessi SM, Carroll KM, Crits-Christoph P, Donovan DM, Kelly JF, Schottenfeld RS, Timko C, Wagner TH. Impact of 12 step mutual help groups on drug use disorder patients across six clinical trials. Drug and Alcohol Dependence 2020; 215:108213.
-
Opioid use disorder in women and the implications for treatment.
Barbosa-Leiker C, Campbell ANC, McHugh RK, Guille C, Greenfield SF. Opioid use disorder in women and the implications for treatment. Psychiatric Research and Clinical Practice 2020;3(1):3-11.
-
Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians.
Randesi M, Rotrosen J, Nunes EV, Lee JD, Novo P, Levran O, Ott J, Pavlicova M, Scodes J, Kreek MJ. Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians. American Journal of Drug and Alcohol Abuse 2020;46(6):761-768.
-
Dental care utilization of hospitalized persons living with HIV and substance use.
Santella AJ, Parish C, Dan R, Feaster DJ, Rodriguez AE, del Rio C, Armstrong WS, Jacobs P, Metsch LR. Dental care utilization of hospitalized persons living with HIV and substance use. Journal of Community Health 2020;46:557-564.